OpenAI is buying Orchestra Bio and plans to add the startup’s team and technology to its life sciences products. The deal will bring Orchestra’s work into Rosalind, OpenAI’s AI model for life sciences research, and Rosalind Workbench.
Orchestra makes AI agents for biotech companies. Its software helps manage the operational details of drug discovery, including tracking finances and resolving scheduling issues in clinical trials.
Rosalind Workbench is designed to help researchers plan experiments and analyze results. OpenAI says Moderna and Novo Nordisk are among the customers already using Rosalind.
Read nextMathematicians dispute OpenAI’s account of its Navier-Stokes proofThe deal terms were not disclosed
The companies did not disclose the terms of the deal. Orchestra had reportedly raised around $20 million as of 2025, with Andreessen Horowitz, Atria and 8VC among its backers.
The purchase shows how major AI labs are building software for industries such as pharmaceuticals. Startups in those markets face the prospect of new products from labs becoming competitors. OpenAI’s stated next step is to bring Orchestra’s team and technology into its Rosalind model and Workbench tool.
